A Phase 2 interventional study of CJC-1134-PC Injection and Weekly placebo for CJC-1134-PC Injection in Type 2 Diabetes Mellitus (T2DM), sponsored by ConjuChem. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-07-19.
Sponsored by ConjuChem · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,609th largest by enrollment of the 2,957 interventional ones that give a count, is one of 152 that started in 2011, is one of 391 in phase 2, and was the 1,176th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,304 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 423 · Phase 2 464 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 152 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,957 interventional studies, 128 across the 336 observational. Of the 2,648 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,486 of 3,304 have an industry lead sponsor. The 10 most frequent:
ConjuChem is the lead sponsor of 4 studies on the registry; none are open to participants now.
ConjuChem has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus (T2DM) on metformin monotherapy. This study will be a randomized, double-blind comparison of CJC-1134-PC versus placebo. Patients taking metformin will continue to take their metformin at the same dose for the duration of the study.
Patients with T2DM, who meet all the inclusion criteria and none of the exclusion criteria, will be randomly assigned to a treatment arm. All patients will undergo weekly clinic visits to receive 17 weeks of study treatment, including the titration period.
CJC-1134-PC or placebo treatment will be administered weekly by subcutaneous injection in the abdomen to patients in a fasting state. Patients will be closely monitored and evaluated for toxicity on an ongoing basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CJC-1134-PC Injection
Drug: CJC-1134-PC Injection
Drug: CJC-1134-PC Injection
Drug: CJC-1134-PC Injection
Drug: Weekly placebo for CJC-1134-PC Injection
CJC-1134-PC administered weekly by subcutaneous injection
Also known as: metformin
Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
Also known as: metformin
Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18
Time frame: CFB to Week 18
Fasting Body Weight CFB to Week 18
Time frame: CFB to Week 18
Time to Hyperglycemia Rescue
Time frame: 18 weeks
| Milestone | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo |
|---|---|---|---|---|---|
| Started | 15 | 15 | 14 | 14 | 15 |
| Completed | 12 | 14 | 11 | 13 | 14 |
| Not completed | 3 | 1 | 3 | 1 | 1 |
| Percent (%) | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo |
|---|---|---|---|---|---|
| Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18 | -0.56 ± 0.597 | -0.56 ± 0.627 | -0.95 ± 0.746 | -0.95 ± 0.828 | -0.13 ± 0.811 |
| kg | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo |
|---|---|---|---|---|---|
| Fasting Body Weight CFB to Week 18 | -1.91 ± 1.624 | -0.14 ± 4.122 | -1.37 ± 2.182 | -0.92 ± 1.999 | -1.85 ± 4.083 |
| days | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo |
|---|---|---|---|---|---|
| Time to Hyperglycemia Rescue | NA ± NA | 47.0 ± 53.74 | NA ± NA | NA ± NA | 57.0 ± NA |
Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Weekly CJC-1134-PC | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Arm 2 - Weekly CJC-1134-PC | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Arm 3 - Weekly CJC-1134-PC | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Arm 4 - Weekly CJC-1134-PC | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Arm 5 - Weekly Placebo | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| Event | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/12 | 7/15 | 5/13 | 6/13 | 1/14 |
| VomitingGastrointestinal disorders | 1/12 | 2/15 | 1/13 | 5/13 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/15 | 1/13 | 3/13 | 2/14 |
| HeadacheNervous system disorders | 0/12 | 2/15 | 0/13 | 1/13 | 1/14 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 2/15 | 0/13 | 0/13 | 1/14 |
| Influenza like illnessGeneral disorders | 1/12 | 1/15 | 0/13 | 1/13 | 0/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 1/15 | 1/13 | 1/13 | 1/14 |
| HypoglycemiaMetabolism and nutrition disorders | 0/12 | 1/15 | 1/13 | 1/13 | 0/14 |
Intent to Treat population
| Age, Customized(Participants) | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo | Total |
|---|---|---|---|---|---|---|
| 18 to 70 years | 15 | 15 | 14 | 14 | 15 | 73 |
| Sex: Female, Male(Participants) | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 7 | 6 | 8 | 4 | 31 |
| Male | 9 | 8 | 8 | 6 | 11 | 42 |
| Race and Ethnicity Not Collected(Participants) | Arm 1 - Weekly CJC-1134-PC | Arm 2 - Weekly CJC-1134-PC | Arm 3 - Weekly CJC-1134-PC | Arm 4 - Weekly CJC-1134-PC | Arm 5 - Weekly Placebo | Total |
|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | 0 |
The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albenatide
ConjuChem